Issue Date: March 10, 2014
Pharma Growth Still Stagnant
Big pharmaceutical companies continue to suffer the ill effects of their decades-long addiction to blockbuster drugs. Many of the multi-billion-dollar sellers that once fueled double-digit profit growth lost patent protection years ago, but companies still have not managed to replace the lost revenues. Last year was no different: Most firms sustained themselves on older drugs still protected by patents.
After a rocky first half, marked for many companies by declines in sales and earnings, the . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society